22.23
-0.33 (-1.46%)
| Previous Close | 22.56 |
| Open | 22.48 |
| Volume | 652,401 |
| Avg. Volume (3M) | 737,385 |
| Market Cap | 662,822,976 |
| Price / Sales | 6.39 |
| Price / Book | 8.89 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 |
| Profit Margin | -159.10% |
| Operating Margin (TTM) | -22.43% |
| Diluted EPS (TTM) | -5.12 |
| Quarterly Revenue Growth (YOY) | 378.80% |
| Total Debt/Equity (MRQ) | 521.34% |
| Current Ratio (MRQ) | 9.51 |
| Operating Cash Flow (TTM) | -135.34 M |
| Levered Free Cash Flow (TTM) | -89.79 M |
| Return on Assets (TTM) | -15.35% |
| Return on Equity (TTM) | -182.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | AnaptysBio, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 5.0 |
| Average | 2.50 |
|
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 4.41% |
| % Held by Institutions | 121.67% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ecor1 Capital, Llc | 31 Mar 2025 | 7,880,094 |
| Palo Alto Investors Lp | 31 Mar 2025 | 1,020,713 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 90.00 (Guggenheim, 304.86%) | Buy |
| Median | 41.00 (84.44%) | |
| Low | 22.00 (HC Wainwright & Co., -1.04%) | Hold |
| Average | 48.50 (118.17%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 18.65 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 28 May 2025 | 90.00 (304.86%) | Buy | 20.90 |
| 06 May 2025 | 54.00 (142.91%) | Buy | 20.12 | |
| Wedbush | 01 May 2025 | 40.00 (79.94%) | Buy | 21.70 |
| JP Morgan | 05 Mar 2025 | 42.00 (88.93%) | Buy | 16.75 |
| HC Wainwright & Co. | 04 Mar 2025 | 22.00 (-1.03%) | Hold | 15.25 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 27 May 2025 | Announcement | Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025 |
| 05 May 2025 | Announcement | Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update |
| 24 Mar 2025 | Announcement | Anaptys Announces Stock Repurchase Plan |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |